HERPES ZOSTER - Treatment

By SWA

Infection: Herpes zoster (immunocompetent host)

  • Drug: Valacyclovir
    • Route: Oral
    • Dosage: 1 g tid × 7 days
  • Drug: Famciclovir
    • Route: Oral
    • Dosage: 500 mg q8h × 7 days
  • Drug: Acyclovir
    • Route: Oral
    • Dosage: 800 mg 5 times daily × 7–10 days

Infection: Herpes zoster (immunocompromised host)

  • Drug: Acyclovir
    • Route: IV
    • Dosage: 10 mg/kg q8h × 7 days
    • Dosage: 800 mg 5 times daily × 7 days
  • Drug: Valacyclovir
    • Route: Oral
    • Dosage: 1 g tid × 7 days
  • Drug: Famciclovir
    • Route: Oral
    • Dosage: 500 mg tid × 10 days

Key Notes:

  • Acyclovir, Valacyclovir, and Famciclovir are the three antivirals commonly used to treat Herpes Zoster (HZ). However, valacyclovir and famciclovir have superior pharmacokinetics and pharmacodynamics and should be used preferentially.
  • Corticosteroids should be added to therapy for HZ in immunocompetent patients. Steroids administered early in the course of localized herpes zoster significantly accelerated quality-of-life improvements as a return to usual activity and termination of analgesic medications.

PREDNISOLONE Dosage Schedule:

  • Days 1-7: 60 mg/day
  • Days 8-14: 30 mg/day
  • Days 15-21: 15 mg/day, then stop

Important Warnings:

  • Glucocorticoids should not be used without concomitant antiviral therapy.
  • Steroids should not be used in patients with HZ who have hypertension, osteoporosis, diabetes mellitus, or are immunocompromised.

Special Considerations for Severely Immunocompromised Hosts:

  • Start treatment with IV acyclovir.
  • If possible, decrease immunosuppressive treatment with IV acyclovir administration.
  • Switch to oral therapy (Valacyclovir 1 g three times a day, Famciclovir 500 mg three times a day, or Acyclovir 800 mg orally five times a day to complete a 10-14-day course) when formation of new lesions has ceased and signs and symptoms of visceral VZV infection are improving.
  • For acyclovir-resistant cases, use Foscarnet 120 mg/kg/day IV in three divided doses for a minimum of 10 days or until lesions heal.

Additional Pain Relief Measures:

  • Aluminum acetate soaks
  • NSAIDs
  • Narcotics
  • Gabapentin
  • Pregabalin
  • Amitriptyline hydrochloride
  • Lidocaine (patches)
  • Fluphenazine hydrochloride

Management of Specific Conditions:

  • Herpes Zoster Ophthalmicus: Managed by an ophthalmologist.
  • Herpes Zoster Oticus: Managed by an otorhinolaryngologist.

Sources:

  1. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th Edition
  2. National AIDS Control Organization (2021), National Guidelines for HIV Care and Treatment
  3. Harrison's Principles of Internal Medicine, 21st Edition 

Note: By reading my blog, you acknowledge that I do not provide medical diagnoses or treatments. The information provided is meant to answer frequently asked questions and is gathered from reputable scientific papers. 

Comments

Post a Comment

Popular posts from this blog

Toxic Skin Condition Post-mRNA COVID-19 Vaccination

By SWA
Image
Identifying Severe Skin Conditions Post-Vaccination Following administration of the BioNTech mRNA vaccine, a small subset of individuals may develop severe and complex reactions. These reactions are often misdiagnosed or misunderstood due to their rarity and diverse presentation. This essay examines a case characterized by severe skin conditions, systemic symptoms, and complications such as hypercalcemia and crystal formation. It highlights the need for accurate diagnosis, holistic management, and increased awareness of these rare but significant vaccine-related adverse events. Initial Symptoms and Misdiagnoses Severe symptoms began shortly after the first dose of the BioNTech vaccine, initially presenting as petechiae, diagnosed by a rheumatologist. However, following the second dose, symptoms rapidly escalated, resulting in intense burning pain and thinning of the skin. The skin on the legs and thighs became paper-thin and could tear with the slightest touch, with the affected area e...
Read more

Dysferlin Protein: Key Roles, Genetic Locations

By SWA
Image
The purpose of this article is to share and discuss the details of a new discovery, which is highlighted within: CRISPR-Cas9: A Breakthrough Tool to Repair the DYSF Gene The dysferlin protein plays an essential role in maintaining the integrity of muscle cell membranes, particularly in tissues that endure significant mechanical stress, such as skeletal and cardiac muscles . Encoded by the DYSF gene , dysferlin is indispensable for repairing damaged cell membranes after injury caused by muscle contraction or external forces. This article explores the main locations where dysferlin is produced, its role in muscle repair, and supportive nutritional and therapeutic strategies for individuals with dysferlin deficiency, such as those affected by dysferlinopathies (e.g., Limb-Girdle Muscular Dystrophy Type 2B or Miyoshi Myopathy). Currently, there is no definitive answer as to why the severity of dysferlin protein expression or depletion varies. Do pathogens play a role in the methylation o...
Read more

Is ME CFS connected to Spinal Muscular Atrophy (SMA) or Post Polio?

By SWA
Image
Today, I understand why Spinal Muscular Atrophy (SMA) received little attention, particularly in the mid-50s. This complex and debilitating genetic illness was poorly understood, and patients' symptoms were often minimized or even dismissed. For more information, please visit the Spinal Muscular Atrophy (SMA) page on MalaCards . Even now, many neurologists lack detailed knowledge of SMA, and comprehensive examinations mentioned in research are rarely pursued. In 2008, while investigating permanent adrenal insufficiency, an MRI ordered by my endocrinologist unexpectedly revealed Chiari Malformation II. However, surgery in 2009 brought no improvement. In 2010, a DNA test showed a genetic marker in the ACTN3 gene: https://www.malacards.org/search/results?q=ACTN3%20gene%20and%20Spinal%20Muscular%20Atrophy%20(SMA) A 2015 MRI revealed ankylosing spondylitis, multiple Tarlov cysts, stenosis at L4 and L5, spinal canal narrowing, and widespread degenerative changes. Surgery on L4 and L5 ...
Read more